

**CLAIMS**

1.     **(Previously Presented)** A kit for the combined use for the treatment of cancer patients, which set comprises the following components:
  - a)     an antigen comprising at least one epitope of a cellular surface protein, or an antibody directed against the cellular surface protein, and
  - b)     an antigen comprising at least one epitope of an aberrant protein glycosylation, or an antibody directed against the aberrant protein glycosylation.
2.     **(Original)** A kit according to claim 1, characterized in that the components a) and b) are contained in one pharmaceutical preparation each or in a single pharmaceutical preparation suitable for immunotherapy.
3.     **(Original)** A kit according to claim 2, characterized in that the pharmaceutical preparation is formulated as a vaccine.
4.     **(Original)** A kit according to claim 2, characterized in that the pharmaceutical preparation is formulated as an intravenously tolerable product.
5.     **(Previously Presented)** A kit according to claim 1, characterized in that the antigen of component a) represents an epitope of a cellular adhesion protein, in particular of a protein selected from the group of EpCAM, NCAM and CEA.
6.     **(Previously Presented)** A kit according to claim 1, characterized in that the antigen of component a) is an epitope of a surface receptor, in particular a receptor molecule selected from the group of the EGF receptor family, CD55 receptor, transferrin receptor and P-glycoprotein.
7.     **(Previously Presented)** A kit according to claim 1, characterized in that the antigen of component b) represents an epitope of a carbohydrate selected from the group of Lewis antigens, in particular Lewis y and/or Lewis b, sialyl-Tn and Globe H.

8. **(Previously Presented)** A kit according to claim 1, characterized in that the antigen of component a) represents an epitope of the EpCAM molecule or of the Her-2/neu receptor, and the antigen of component b) represents an epitope of the Lewis Y molecule\_
9. **(Previously Presented)** A method for the immunologic determination of tumor cells of a solid tumor or disseminated tumor cells of a cancer disease which comprises
- a) exposing a sample from a cancer patient to:
    - (i) an antigen comprising at least one epitope of a cellular surface protein, or an antibody directed against the cellular surface protein, and
    - (ii) an antigen comprising at least one epitope of an aberrant protein glycosylation, or an antibody directed against the aberrant protein glycosylation; and
  - b) determining the immunological response.
10. **(Previously Presented)** The method according to claim 9, wherein the determination is carried out within the scope of the treatment of cancer patients.
11. **(Previously Presented)** The method according to claim 9, wherein said sample comprise tumor cells from samples of peripheral blood or bone marrow.
12. **(Previously Presented)** The method according to claim 9 or 10, wherein an antibody titer against the antigens of the components is determined.
13. **(Previously Presented)** The method according to claim 12, wherein the determination is carried out for monitoring a treatment of a cancer patient.
14. **(Previously Presented)** A method for immunologic selection of a tumor-specific target antigen or of antibodies directed against the target antigen by exposing a sample from a cancer patient to

- (a) an antigen comprising at least one epitope of a cellular surface protein, or an antibody directed against the cellular surface protein, and
- (b) an antigen comprising at least one epitope of an aberrant protein glycosylation, or an antibody directed against the aberrant protein glycosylation; wherein the antigen is a neoepitope which is formed by the glycosylation of an antigen of component a) with an antigen of component b).

15. **(Previously Presented)** An antigen composition which comprises a neoepitope or its mimic, prepared by the method according to claim 14.

16. **(Previously Presented)** A composition according to claim 15 wherein the antigen is a naturally occurring antigen or a fragment thereof.

17. **(Previously Presented)** A method according to claim 14, wherein an antibody directed against the neoepitope is selected and prepared by using a kit according to claim 1.

18. **(Previously Presented)** An antibody composition with specificity for a neo-epitope, prepared by the method according to claim 17.

19. **(Original)** A diagnostic agent based on a kit according to claim 1, characterized in that it contains a reagent for determining an immune reaction with components a) and b), or with antibodies against these.

20. **(Previously Presented)** An agent according to claim 19, wherein the reagent is labelled with a fluorescent agent, a chromogen, a radiolabel or an enzyme.

21. **(Previously Presented)** An agent according to claim 20, wherein the reagent is immobilized on a carrier.

22. **(Previously Presented)** An agent according to claim 21, wherein the carrier is a matrix for immunoaffinity chromatography.

23. **(New)** A kit according to claim 1, wherein said antigen of paragraph (a) is EpCAM, and said antigen of paragraph (b) is Lewis Y.